Retail skepticism of FDA official's critique fueled rebound from recent selloff

 

The stock surged amid widespread social media discussion and trader commentary dismissing recent public criticisms from an FDA official labeling uniQure's AMT-130 Huntington's gene therapy data as insufficient or a "failure." Posts highlighted perceived overreach by the agency, including clarifications on sham surgery requirements and contrasts with prior analyst views (e.g., Stifel), suggesting diminished FDA credibility. This sparked bullish options flow, short covering, and momentum buying on elevated volume, extending recovery from the 40%+ plunge earlier in the week triggered by the March 2 regulatory update requiring a new placebo-controlled study. No new company announcements occurred.

https://finviz.com/quote.ashx?t=QURE&p=d